Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MLYCD | O95822 | 2/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 2/20 | 0.31 |
| ▸ | CA5A | P35218 | 2/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6429491 | 0.83 | CA2 (0.46) | CA2ALDH1A1POLBSMN1; SMN2ESR1 | |
| SCHEMBL958597 | 0.79 | CA2 (0.46) | CA2ALDH1A1POLBSMN1; SMN2ESR1 | |
| SCHEMBL7219098 | 0.77 | CA2 (0.43) | CA2ALDH1A1POLBSMN1; SMN2ESR1 | |
| SCHEMBL865062 | 0.77 | CA2 (0.43) | CA2ALDH1A1POLBSMN1; SMN2ESR1 | |
| Hydrochloric Acid SCHEMBL29891850 | 0.77 | MLYCD (0.44) | CA2ALDH1A1POLBSMN1; SMN2ESR1 | |
| SCHEMBL25135063 | 0.75 | TAS1R3 (0.46) | CA2ALDH1A1POLBSMN1; SMN2ESR1 | |
| SCHEMBL24687767 | 0.75 | CA2 (0.42) | CA2ALDH1A1POLBSMN1; SMN2ESR1 | |
| SCHEMBL7281863 | 0.75 | CA2 (0.42) | CA2ALDH1A1POLBSMN1; SMN2ESR1 | |
| SCHEMBL25135055 | 0.75 | TAS1R3 (0.46) | CA2ALDH1A1POLBSMN1; SMN2ESR1 | |
| SCHEMBL22298130 | 0.75 | CA2 (0.42) | CA2ALDH1A1POLBSMN1; SMN2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211241-B2 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-01 | — | — | US | disclosed |
| US-6861043-B2 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | SCHERING AG (DE) | 2005-03-01 | — | — | US | disclosed |
| US-20040091426-A1 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-05-13 | — | — | US | disclosed |
| US-20020187101-A1 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | SCHERING AG (DE) | 2002-12-12 | — | — | US | disclosed |
| US-6426059-B1 | NUCLEAR MAGNETIC RESONANCE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-07-30 | — | — | US | disclosed |
| US-6248306-B1 | MEDICAL DIAGNOSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-06-19 | — | — | US | disclosed |
| US-6177060-B1 | NMR OR X-RAY LYMPHOGRAPHY IMAGES | SCHERING AKTIENGESEUSCHAFT (DE) | 2001-01-23 | — | — | US | disclosed |
| US-6166200-A | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-12-26 | — | — | US | disclosed |
| US-6063361-A | ADMINISTERING TO A PATIENT AT LEAST ONE CASCADE POLYMER COMPLEX AND SUBJECTING THE PATIENT TO A RADIOLOGY DIAGNOSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-05-16 | — | — | US | disclosed |
| US-6057419-A | DRUGS AND IMAGES | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-05-02 | — | — | US | disclosed |
| US-5874061-A | PARAMAGNETIC CONTRAST AGENTS FOR BOTH NUCLEAR SPIN AND COMPUTOR TOMOGRAPHY AND MAGNETIC RESONANCE IMAGING; MARKING VASCULAR SPACE (BLOOD-POOL AGENTS); BIOCOMPATIBILITY; HIGH SIGNAL INTENSITY, THEREFORE A LOWER DOSAGE USED | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-02-23 | — | — | US | disclosed |
| US-5820849-A | DIAGNOSIS WITH NUCLEAR MAGNETIC RESONANCE | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040091426-A1 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | ZYX, CCNY, MOK | CA2 838/4885ALDH1A1 4835/4885POLB 88/4885 |
| US-20020187101-A1 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | TFPI, LYN, SYK | CA2 3368/4885ALDH1A1 4854/4885POLB 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.